{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:24:40Z","timestamp":1762971880918,"version":"3.45.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23302-6","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:20:48Z","timestamp":1762971648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new, patient-friendly, needleless methotrexate administration method using the pyro-drive jet injector in rats"],"prefix":"10.1038","volume":"15","author":[{"given":"Mikiko","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"23302_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"23302_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken). 73, 924\u2013939 (2021).","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"23302_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"23302_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda, H. et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod. Rheumatol. 29, 31\u201340 (2019).","journal-title":"Mod. Rheumatol."},{"key":"23302_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jps.2600780219","volume":"78","author":"RA Herman","year":"1989","unstructured":"Herman, R. A., van Pedersen, P., Hoffman, J., Koehnke, R. & Furst, D. E. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci. 78, 165\u2013171 (1989).","journal-title":"J. Pharm. Sci."},{"key":"23302_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","volume":"29","author":"K Inoue","year":"2014","unstructured":"Inoue, K. & Yuasa, H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab. Pharmacokinet. 29, 12\u201319 (2014).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"23302_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2217\/pgs.14.116","volume":"15","author":"A Lima","year":"2014","unstructured":"Lima, A. et al. Genetic polymorphisms in low-dose methotrexate transporters: Current relevance as methotrexate therapeutic outcome biomarkers. Pharmacogenomics 15, 1611\u20131635 (2014).","journal-title":"Pharmacogenomics"},{"key":"23302_CR8","first-page":"305","volume":"13","author":"P Moya","year":"2017","unstructured":"Moya, P., Corominas, H., Salazar, J. & D\u00edaz-Torn\u00e9, C. A step forward in methotrexate pharmacogenetics. Rheumatol. Clin. 13, 305 (2017).","journal-title":"Rheumatol. Clin."},{"key":"23302_CR9","first-page":"1047","volume":"27","author":"J Tukov\u00e1","year":"2009","unstructured":"Tukov\u00e1, J., Chl\u00e1dek, J., Nemcov\u00e1, D., Chl\u00e1dkov\u00e1, J. & Dolezalov\u00e1, P. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 27, 1047\u20131053 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"23302_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","volume":"73","author":"S Pavy","year":"2006","unstructured":"Pavy, S. et al. Methotrexate therapy for rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73(4), 388\u2013395 (2006).","journal-title":"Joint Bone Spine"},{"key":"23302_CR11","first-page":"S83","volume":"22","author":"R Rau","year":"2004","unstructured":"Rau, R. & Herborn, G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin. Exp. Rheumatol. 22, S83-94 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"23302_CR12","first-page":"1845","volume":"20","author":"JW Jundt","year":"1993","unstructured":"Jundt, J. W., Browne, B. A., Fiocco, G. P., Steele, A. D. & Mock, D. A comparison of low dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J. Rheumatol. 20, 1845\u20131849 (1993).","journal-title":"J. Rheumatol."},{"key":"23302_CR13","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra, M. et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J. Rheumatol. 31, 645\u2013648 (2004).","journal-title":"J. Rheumatol."},{"key":"23302_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff, M. H., Jaffe, J. S. & Freundlich, B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses of 15 mg may be overcome with subcutaneous administration. Ann. Rheum. Dis. 73, 1549\u20131551 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"23302_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun, J. et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 58, 73\u201381 (2008).","journal-title":"Arthritis Rheum."},{"key":"23302_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood, G. S. et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann. Rheum. Dis. 75, 1003\u20131008 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"23302_CR17","unstructured":"Interview Form for METJECT Subcutaneous Injection Syringe\/Pen, 6th ed. (Eisai Co., Ltd, 2024)."},{"key":"23302_CR18","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.xphs.2019.02.021","volume":"108","author":"H Miyazaki","year":"2019","unstructured":"Miyazaki, H., Atobe, S., Suzuki, T., Iga, H. & Terai, K. Development of Pyro-Drive Jet Injector with controllable jet pressure. J. Pharm. Sci. 108, 2415\u20132420 (2019).","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"23302_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/vaccines10091427","volume":"10","author":"H Nakagami","year":"2022","unstructured":"Nakagami, H. et al. Phase I study to assess the safety and immunogenicity of an intradermal COVID-19 DNA vaccine administered using a Pyro-Drive Jet Injector in healthy adults. Vaccines (Basel) 10(9), 1427 (2022).","journal-title":"Vaccines (Basel)"},{"key":"23302_CR20","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1093\/rheumatology\/keaf054","volume":"64","author":"L Qiao","year":"2025","unstructured":"Qiao, L. et al. Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA. Rheumatology (Oxford) 64, 3426\u20133433 (2025).","journal-title":"Rheumatology (Oxford)"},{"key":"23302_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/mr\/roac103","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka, Y. et al. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Mod. Rheumatol. 33, 680\u2013689 (2023).","journal-title":"Mod. Rheumatol."},{"key":"23302_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12891-016-1254-x","volume":"17","author":"JR Curtis","year":"2016","unstructured":"Curtis, J. R. et al. Patient\u2019s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet. Disord. 17, 405 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"23302_CR23","first-page":"483","volume":"22","author":"MS Islam","year":"2013","unstructured":"Islam, M. S. et al. Comparative efficacy of subcutaneous vs oral methotrexate in active rheumatoid arthritis. Mymensingh Med. J. 22, 483\u2013488 (2013).","journal-title":"Mymensingh Med. J."},{"key":"23302_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon, J. & Rogers, M. The fear of needles: A systematic review and meta-analysis. J. Adv. Nurs. 75, 30\u201342 (2019).","journal-title":"J. Adv. Nurs."},{"key":"23302_CR25","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.05.005","volume":"121","author":"DR Johnson","year":"2008","unstructured":"Johnson, D. R., Nichol, K. L. & Lipczynski, K. Barriers to adult immunization. Am. J. Med. 121, S28\u2013S35 (2008).","journal-title":"Am. J. Med."},{"key":"23302_CR26","first-page":"886","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","unstructured":"Centers for Disease Control and Prevention (CDC). Reasons reported by Medicare beneficiaries for not receiving influenza and pneumococcal vaccinations\u2014United States, 1996. MMWR Morb. Mortal. Wkl. Rep. 48, 886 (1999).","journal-title":"MMWR Morb. Mortal. Wkl. Rep."},{"key":"23302_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/RHU.0000000000000117","volume":"20","author":"B Freundlich","year":"2014","unstructured":"Freundlich, B., Kivitz, A. & Jaffe, J. S. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: Results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J. Clin. Rheumatol. 20, 256\u2013260 (2014).","journal-title":"J. Clin. Rheumatol."},{"key":"23302_CR28","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/1097-0142(197511)36:5<1619::AID-CNCR2820360514>3.0.CO;2-G","volume":"36","author":"M Freeman-Narrod","year":"1975","unstructured":"Freeman-Narrod, M., Gerstley, B. J., Engstrom, P. F. & Bornstein, R. S. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 36, 1619\u20131624 (1975).","journal-title":"Cancer"},{"key":"23302_CR29","unstructured":"Package Insert of Metoject\u00ae Subcutaneous Injection Syringe\/Pen, 6th ed. (Eisai Co., Ltd, 2024)."},{"key":"23302_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12249-019-1564-z","volume":"21","author":"C Chang","year":"2019","unstructured":"Chang, C. et al. Stable immune response induced by intradermal DNA vaccination by a novel needleless Pyro-Drive Jet Injector. AAPS PharmSciTech 21, 19 (2019).","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"23302_CR31","first-page":"286","volume":"14","author":"K Tabata","year":"1999","unstructured":"Tabata, K. et al. Moment analysis program available on Microsoft Excel\u24c7. Xenobio. Metabol. Dispos. 14(4), 286\u2013293 (1999).","journal-title":"Xenobio. Metabol. Dispos."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23302-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:20:49Z","timestamp":1762971649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23302-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23302"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23302-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39599"}}